Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palbociclib + CPX-351
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
This combination therapy involves palbociclib, a small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), and CPX-351, a liposomal encapsulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio. Palbociclib is used to induce G1 cell cycle arrest in acute myeloid leukemia (AML) cells, theoretically synchronizing them to increase their sensitivity to the S-phase specific cytotoxic effects of CPX-351. This approach is being investigated in Phase I/II trials led by Dr. Sudipto Mukherjee for patients with newly diagnosed or relapsed/refractory AML, particularly those with secondary AML or therapy-related AML. The liposomal delivery of CPX-351 allows for prolonged exposure and preferential uptake by bone marrow leukemia cells, while palbociclib acts as a cell cycle modulator to enhance the efficacy of the chemotherapy backbone.
- Brand names
- IbranceVyxeos
- Other names
- palbociclibCPX-351CPX351CPX 351liposomal cytarabine and daunorubicindaunorubicin and cytarabine liposome
02
Targets
DNACDK6 (Cyclin-dependent kinase 6)DNA polymerase familyCDK4 (Cyclin-dependent kinase 4)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on palbociclib + CPX-351.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palbociclib + CPX-351.